[A placebo-controlled, double-blind, randomized trial of single daily dose of anti-muscarinic drug solifenacin succinate in patients with overactive bladder]

Akush Ginekol (Sofiia). 2007;46(5):55-7.
[Article in Bulgarian]
No abstract available

Publication types

  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Humans
  • Male
  • Muscarinic Antagonists / administration & dosage
  • Muscarinic Antagonists / adverse effects
  • Muscarinic Antagonists / therapeutic use*
  • Quinuclidines / administration & dosage
  • Quinuclidines / adverse effects
  • Quinuclidines / therapeutic use*
  • Solifenacin Succinate
  • Tetrahydroisoquinolines / administration & dosage
  • Tetrahydroisoquinolines / adverse effects
  • Tetrahydroisoquinolines / therapeutic use*
  • Treatment Outcome
  • Urinary Bladder, Overactive / drug therapy*
  • Urinary Bladder, Overactive / metabolism
  • Urination / drug effects

Substances

  • Muscarinic Antagonists
  • Quinuclidines
  • Tetrahydroisoquinolines
  • Solifenacin Succinate